SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING GLIPIZIDE AND METHOD FOR PRODUCING SAME

摘要

A monolithic sustained release composition of glipizide for patients with non-insulin dependent diabetes mellitus that exhibits a breakdown after ingestion by a patient in conformity with a zero-order kinetic. A composition of a glipizide and a hydrocolloid forming agent and optimally other auxiliary excipients for the sustained release of glipizide. Hydrophilic material may comprise at least 50 % by weight of the composition. A process for producing the composition, which includes the steps of granulating glipizide, a hydrophilic material and a diluent, drying the granulated product and lubricating the product with a flow regulating agent and lubricant.